 |
16 Diseases |  |
13 Trials |
|
13 Trials |  |
579 News |  |
| «1234567» |
- | Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
New P2a trial: SPECTRA: A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (clinicaltrials.gov) - Nov 13, 2018
P2a, N=25, Not yet recruiting, Sponsor: Acceleron Pharma, Inc.
- | Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Trial completion date, Combination therapy: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 21, 2018
P1, N=34, Recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Dec 2018 --> Aug 2019
- | sotatercept (ACE-011) / Acceleron, BMS
Clinical, P2 data, Journal: Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. (Pubmed Central) - Aug 9, 2018
P2
Sotatercept, a novel activin-receptor fusion protein, was well tolerated and effective for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes in whom previous ESA treatment had failed. Treatment with sotatercept could be beneficial for these patients who have few available treatment options.
- ||| Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Trial completion: Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov) - Jun 14, 2018
P2, N=74, Completed, Sponsor: Celgene
Treatment with sotatercept could be beneficial for these patients who have few available treatment options. Active, not recruiting --> Completed
- | Review, Journal: Developmental Therapeutics in Myeloproliferative Neoplasms. (Pubmed Central) - Apr 24, 2018
In polycythemia vera, a novel interferon administered every 2 weeks is being developed for front-line therapy in high-risk individuals, and inhibitors of human double minute 2 (HDM2) have shown promise in preclinical studies, as have HDAC inhibitors such as givinostat (both in the laboratory and in the clinic). Ruxolitinib is approved for second-line therapy of polycythemia vera and is being developed for essential thrombocythemia.
- ||||| sotatercept (MK-7962) / BMS, Merck (MSD)
New P2 trial: PULSAR: A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Apr 11, 2018
P2, N=90, Not yet recruiting, Sponsor: Acceleron Pharma, Inc.
- ||| sotatercept (MK-7962) / BMS, Merck (MSD)
Enrollment change, Trial completion date, Trial primary completion date: Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov) - Mar 6, 2018
P2, N=100, Active, not recruiting, Sponsor: Celgene
Ruxolitinib is approved for second-line therapy of polycythemia vera and is being developed for essential thrombocythemia. N=74 --> 100 | Trial completion date: Jul 2018 --> Apr 2018 | Trial primary completion date: Aug 2015 --> Apr 2018
- || Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Trial completion date: Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia (clinicaltrials.gov) - Mar 3, 2018
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=74 --> 100 | Trial completion date: Jul 2018 --> Apr 2018 | Trial primary completion date: Aug 2015 --> Apr 2018 Trial completion date: Feb 2020 --> Feb 2021
- | Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 13, 2018
P1, N=34, Recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Feb 2020 --> Feb 2021 Trial primary completion date: Dec 2017 --> May 2018 | Trial completion date: Jun 2018 --> Dec 2018
- | sotatercept (MK-7962) / BMS, Merck (MSD)
Trial primary completion date: Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia (clinicaltrials.gov) - Jan 24, 2018
P1/2, N=20, Recruiting, Sponsor: Northwell Health
Trial primary completion date: Dec 2017 --> May 2018 | Trial completion date: Jun 2018 --> Dec 2018 Trial primary completion date: Dec 2017 --> Mar 2019
- || Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Trial primary completion date: Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia (clinicaltrials.gov) - Jan 5, 2018
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2017 --> Mar 2019 Trial primary completion date: Feb 2019 --> Feb 2020
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Trial primary completion date, Metastases: Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012) (clinicaltrials.gov) - Nov 18, 2017
P2, N=30, Terminated, Sponsor: Celgene
Trial primary completion date: Feb 2019 --> Feb 2020 Trial primary completion date: Apr 2011 --> Nov 2010
- sotatercept (MK-7962) / BMS, Merck (MSD)
Phase classification: A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis. (clinicaltrials.gov) - Mar 8, 2017
P2a, N=50, Completed, Sponsor: Celgene
Trial primary completion date: Apr 2011 --> Nov 2010 Phase classification: P2 --> P2a
- | Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Trial completion: A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis (clinicaltrials.gov) - Feb 16, 2017
P2, N=49, Completed, Sponsor: Celgene
Phase classification: P2 --> P2a Active, not recruiting --> Completed
- || Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Trial primary completion date: Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia (clinicaltrials.gov) - Jan 4, 2017
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Feb 2018 --> Feb 2019
- || sotatercept (MK-7962) / BMS, Merck (MSD)
Trial primary completion date: Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov) - Dec 2, 2016
P2, N=74, Active, not recruiting, Sponsor: Celgene Corporation
Trial primary completion date: Feb 2018 --> Feb 2019 Trial primary completion date: Jun 2016 --> Aug 2015
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Combination therapy: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 21, 2016
P1, N=34, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jun 2016 --> Aug 2015 Trial primary completion date: Jun 2016 --> Dec 2017
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Phase classification: A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma (clinicaltrials.gov) - Oct 27, 2016
P2a, N=30, Completed, Sponsor: Celgene Corporation
Trial primary completion date: Jun 2016 --> Dec 2017 Phase classification: P2 --> P2a
- sotatercept (MK-7962) / BMS, Merck (MSD)
Enrollment change, Trial withdrawal, Trial primary completion date: A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma (clinicaltrials.gov) - Sep 1, 2016
P2a, N=0, Withdrawn, Sponsor: Rebecca Silbermann
Phase classification: P2 --> P2a N=20 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2017 --> Apr 2016
- sotatercept (MK-7962) / BMS, Merck (MSD)
Enrollment open, Trial primary completion date: Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia (clinicaltrials.gov) - Jun 18, 2016
P1/2, N=20, Recruiting, Sponsor: Northwell Health
N=20 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2017 --> Apr 2016 Active, not recruiting --> Recruiting | Trial primary completion date: Apr 2016 --> Dec 2017
- ||| Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Enrollment change: Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia (clinicaltrials.gov) - Jun 10, 2016
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting | Trial primary completion date: Apr 2016 --> Dec 2017 N=50 --> 60
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Trial primary completion date: A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis (clinicaltrials.gov) - May 6, 2016
P2, N=49, Active, not recruiting, Sponsor: Celgene Corporation
N=50 --> 60 Trial primary completion date: Mar 2016 --> Aug 2016
- | sotatercept (MK-7962) / BMS, Merck (MSD)
Trial completion: A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis. (clinicaltrials.gov) - Mar 18, 2016
P2, N=50, Completed, Sponsor: Celgene Corporation
Trial primary completion date: Mar 2016 --> Aug 2016 Recruiting --> Completed
- | Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Enrollment closed: A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis (clinicaltrials.gov) - Mar 2, 2016
P2, N=49, Active, not recruiting, Sponsor: Celgene Corporation
Recruiting --> Completed Recruiting --> Active, not recruiting
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Trial primary completion date: Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia (clinicaltrials.gov) - Feb 29, 2016
P2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2017 --> Feb 2018
- sotatercept (MK-7962) / BMS, Merck (MSD)
Trial primary completion date: A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 23, 2016
P2a, N=20, Recruiting, Sponsor: Rebecca Silbermann
Trial primary completion date: Feb 2017 --> Feb 2018 Trial primary completion date: Jan 2016 --> Jan 2017
- sotatercept (MK-7962) / BMS, Merck (MSD)
Trial primary completion date: A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma (clinicaltrials.gov) - Oct 5, 2015
P2a, N=20, Recruiting, Sponsor: Rebecca Silbermann
Trial primary completion date: Jan 2016 --> Jan 2017 Trial primary completion date: Oct 2015 --> Jan 2016
- sotatercept (MK-7962) / BMS, Merck (MSD)
Enrollment closed, Trial primary completion date: Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia (clinicaltrials.gov) - Sep 3, 2015
P1/2, N=20, Active, not recruiting, Sponsor: North Shore Long Island Jewish Health System
Trial primary completion date: Oct 2015 --> Jan 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Apr 2016
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Combination therapy: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 25, 2015
P1, N=34, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Apr 2016 Trial primary completion date: Feb 2015 --> Jun 2016
- ||| sotatercept (MK-7962) / BMS, Merck (MSD)
Enrollment closed, Enrollment change, Trial primary completion date: Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov) - Aug 20, 2015
P2, N=74, Active, not recruiting, Sponsor: Celgene Corporation
Trial primary completion date: Feb 2015 --> Jun 2016 Recruiting --> Active, not recruiting | N=100 --> 74 | Trial primary completion date: Jun 2015 --> Jun 2016
- sotatercept (MK-7962) / BMS, Merck (MSD)
Trial primary completion date: A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis. (clinicaltrials.gov) - Aug 19, 2015
P2, N=43, Recruiting, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting | N=100 --> 74 | Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Jul 2015 --> Jan 2016
- | sotatercept (MK-7962) / BMS, Merck (MSD)
Enrollment closed, Phase classification, Enrollment change, Trial initiation date: Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( ?)- Thalassemia. (clinicaltrials.gov) - Aug 19, 2015
P2a, N=46, Active, not recruiting, Sponsor: Celgene Corporation
Trial primary completion date: Jul 2015 --> Jan 2016 Recruiting --> Active, not recruiting | Phase classification: P2 --> P2a | N=85 --> 46 | Initiation date: Mar 2012 --> Oct 2012
- || Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Trial primary completion date: A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis (clinicaltrials.gov) - Jun 24, 2015
P2, N=60, Recruiting, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting | Phase classification: P2 --> P2a | N=85 --> 46 | Initiation date: Mar 2012 --> Oct 2012 Trial primary completion date: Sep 2015 --> Mar 2016
- sotatercept (MK-7962) / BMS, Merck (MSD)
Trial primary completion date: A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis. (clinicaltrials.gov) - Jun 24, 2015
P2, N=43, Recruiting, Sponsor: Celgene Corporation
Trial primary completion date: Sep 2015 --> Mar 2016 Trial primary completion date: Mar 2015 --> Jul 2015
- | Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Enrollment open: Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia (clinicaltrials.gov) - Apr 25, 2015
P2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Mar 2015 --> Jul 2015 Active, not recruiting --> Recruiting
- | Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Enrollment closed: Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia (clinicaltrials.gov) - Apr 6, 2015
P2, N=50, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | sotatercept (MK-7962) / BMS, Merck (MSD)
Enrollment open: A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma (clinicaltrials.gov) - Nov 5, 2014
P2a, N=20, Recruiting, Sponsor: Indiana University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| sotatercept (MK-7962) / BMS, Merck (MSD)
Enrollment change, Trial primary completion date: Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( ?)- Thalassemia. (clinicaltrials.gov) - Sep 10, 2014
P2, N=85, Recruiting, Sponsor: Celgene Corporation
Not yet recruiting --> Recruiting N=65 --> 85 | Trial primary completion date: Apr 2014 --> Jun 2015
- | sotatercept (MK-7962) / BMS, Merck (MSD)
New P2a trial: A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma (clinicaltrials.gov) - Sep 4, 2014
P2a, N=20, Not yet recruiting, Sponsor: Indiana University
- || sotatercept (MK-7962) / BMS, Merck (MSD)
Trial primary completion date: Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov) - Aug 6, 2014
P2, N=100, Recruiting, Sponsor: Celgene Corporation
N=65 --> 85 | Trial primary completion date: Apr 2014 --> Jun 2015 Trial primary completion date: Mar 2014 --> Jun 2015
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Combination therapy: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - May 27, 2014
P1, N=34, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Mar 2014 --> Jun 2015 Trial primary completion date: Feb 2014 --> Feb 2015
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Combination therapy: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - May 27, 2014
P1, N=34, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Feb 2014 --> Feb 2015 Trial completion date: Aug 2014 --> Aug 2015
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Enrollment change: Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia (clinicaltrials.gov) - May 8, 2014
P2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Aug 2014 --> Aug 2015 N=40 --> 50
- sotatercept (MK-7962) / BMS, Merck (MSD)
Enrollment open: Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia (clinicaltrials.gov) - Feb 26, 2014
P1/2, N=20, Recruiting, Sponsor: North Shore Long Island Jewish Health System
N=40 --> 50 Suspended --> Recruiting
- |||| Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Enrollment open: A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis (clinicaltrials.gov) - Dec 5, 2013
P2, N=60, Recruiting, Sponsor: Celgene Corporation
Suspended --> Recruiting Not yet recruiting --> Recruiting
- ||||| Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
New P2 trial: A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis (clinicaltrials.gov) - Dec 1, 2013
P2, N=60, Recruiting, Sponsor: Celgene Corporation
- ||| sotatercept (MK-7962) / BMS, Merck (MSD)
Enrollment change: Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( ?)- Thalassemia. (clinicaltrials.gov) - Nov 21, 2013
P2, N=65, Recruiting, Sponsor: Celgene Corporation
Not yet recruiting --> Recruiting N=45 --> 65
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Trial termination: Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors (clinicaltrials.gov) - Apr 7, 2013
P2, N=4, Terminated, Sponsor: Celgene Corporation
Recruiting --> Terminated; Isotope needed to conduct RBC/PV analysis (primary endpoint) no longer available from manufacturer. No alternatives available for use.
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Enrollment change: Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors (clinicaltrials.gov) - Apr 7, 2013
P2, N=4, Terminated, Sponsor: Celgene Corporation
No alternatives available for use. N=11 --> 4
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Combination therapy: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 18, 2013
P1, N=34, Recruiting, Sponsor: Massachusetts General Hospital
N=11 --> 4 Suspended --> Recruiting